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AbstrACt
Objective To obtain pilot data to evaluate the 
discriminatory power of biomarkers microRNA-122 (miR-
122), high-mobility group box 1 (HMGB1), full-length 
keratin-18 (flk-18) and caspase-cleaved keratin-18 (cck-
18) in plasma to identify potential biliary complications 
that may require acute intervention.
Design An observational biomarker cohort pilot study.
setting In a Scottish University teaching hospital for 12 
months beginning on 3 September 2014.
Participants Blood samples were collected from adults 
(≥16 years old) referred with acute biliary-type symptoms 
who have presented to hospital within 24 hours prior were 
recruited. Patients unable or refused to give informed 
consent or were transferred from a hospital outside the 
National Health Service regional trust were excluded.
Primary outcome measures To evaluate whether 
circulating miR-122, HMGB1, flk-18 and cck-18 can 
discriminate between people with and without gallstone 
disease and uncomplicated from complicated gallstone 
disease during the first 24 hours of hospital admission.
results 300 patients were screened of which 285 
patients were included. Plasma miR-122, cck-18 and 
flk-18 concentrations were increased in patients with 
gallstones compared with those without (miR-122: 
median: 2.89×104 copies/mL vs 0.90×104 copies/mL 
(p<0.001); cck-18: 121.2 U/L vs 103.5 U/L (p=0.031); 
flk-18: 252.4 U/L vs 145.1 U/L (p<0.001)). Uncomplicated 
gallstone disease was associated with higher miR-122 and 
cck-18 concentrations than complicated disease (miR-122: 
5.72×104 copies/mL vs 2.26×104 copies/mL (p=0.023); 
cck-18: 139.7 U/L vs 113.6 U/L (p=0.047)). There was no 
significant difference in HMGB1 concentration between 
patients with and without gallstones (p=0.559). Separation 
between groups for all biomarkers was modest.
Conclusion miR-122 and keratin-18 plasma 
concentrations are elevated in patients with gallstones. 
However, this result is confounded by the association 
between biomarker concentrations, age and gender. In this 
pilot study, miR-122 and keratin-18 were not sufficiently 
discriminatory to be progressed as clinically useful 
biomarkers in this context.
IntrODuCtIOn 
Gallstone disease is one of the most common 
reasons for persons to present to hospital 
with gastrointestinal disease in Western coun-
tries.1 In the UK, there are approximately 
330 people per 100 000 adult population 
admitted with an acute biliary disease annu-
ally.2 A point-of-care diagnostic test that can 
stratify patients with acute biliary-type symp-
toms according to their need for further 
investigation or intervention will be advan-
tageous to patients and has the potential to 
reduce healthcare expenditure. Individuals 
with uncomplicated biliary colic and aseptic 
choledocholithiasis may be safely discharged 
without the need for inpatient management 
strengths and limitations of this study
 ► Laboratory analyses were carried out blinded to clin-
ical data.
 ► The study only included patients who had present-
ed to hospital within 24 hours, thus ensuring that 
biomarker concentration levels would be as closely 
representative of the patients’ presenting condition 
as possible.
 ► Sample size of study is relatively small.
 ► Serial patient blood sampling for biomarker analyses 
may have been useful to determine the true nature 
of biomarker concentration changes as the biliary 
diseases progress.
 ► microRNA-122 and keratin-18 plasma concentra-
tions are confounded by age and gender.
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and can be managed in an outpatient or day-case setting. 
Conversely, patients with complications, for example, 
cholecystitis, cholangitis and gallstone pancreatitis are 
best managed as inpatients according to current national 
standards.
Standard available clinicopathological data for patients 
presenting acutely with gallstones in the emergency 
setting include clinical history and examination, routine 
laboratory results and ultrasound scan (USS) or MRI find-
ings.3 Currently, this set of investigations cannot always 
identify whether patients have complications of gallstones 
that necessitate admission. Therefore, a biomarker panel 
that could be used as an adjunct to existing investiga-
tions to guide treatment decisions would be extremely 
advantageous.
microRNA-122 (miR-122), high-mobility group box 1 
(HMGB1), full-length keratin-18 (flk-18) and caspase-
cleaved keratin-18 (cck-18) have been identified as 
early acute hepatic injury biomarkers at presentation 
to hospital, particularly in the context of paracetamol 
overdose.4 5 miRs are single stranded, small non-pro-
tein-coding RNAs. miR-122 is expressed near exclusively 
in the hepatocyte and provides enhanced hepatic speci-
ficity over all current liver injury biomarkers.6 miR-122 
is important in the regulation of cholesterol and fatty 
acid metabolism; these mechanisms are key contributors 
to the pathogenesis of gallstones.7 8 HMGB1 is a nucle-
ar-binding protein with proinflammatory activity that is 
released by immune and necrotic cells.9 10 Keratins are 
part of the intermediate filament system and they play 
an important role in cellular mechanisms. They are 
a hallmark of epithelial cells, including hepatocytes 
and biliary cells.11 12 During apoptosis, flk-18 is cleaved 
by caspases to produce the fragment cck-18.13 flk-18 is 
released into blood during necrosis and cck-18 during 
apoptosis.14 Although these biomarkers (particularly 
miR-122) are enriched specifically in hepatocyte, studies 
in preclinical models have demonstrated increased circu-
lating miR-122, HMGB1 and keratin-18 following bile 
duct ligation,15 which may reflect subsequent hepatocyte 
injury. In humans with cholecystitis, keratin-18 has been 
reported to be elevated in both bile and serum samples, 
when compared with a control group of healthy volun-
teers.16 Shifeng et al6 reported that circulating miR-122 
has a high diagnostic value with regard to distinguishing 
patients with biliary calculi from normal controls. In that 
study, the area under the receiver operator curve) was 
0.93, which suggests very high accuracy. However, the 
controls were healthy subjects, whereas in clinical prac-
tice, the relevant comparison group will be patients with 
other aetiologies of abdominal pain. In the present study, 
we recruited a cohort of patients with acute abdominal 
pain.
The aim of this pilot study was to obtain sufficient data 
to make a go/no-go decision regarding progression to a 
larger scale study to evaluate whether circulating hepatic 
injury biomarkers discriminate between people with 
and without gallstone disease and uncomplicated from 
complicated gallstone disease during the first 24 hours of 
hospital admission.
MethODs
Patient and public involvement
The research question and outcome measures developed 
as a result of the high incidence of gallstone diseases and 
the clinical significance they have on patients’ health 
and quality of life. Patients were only involved as study 
participants and not in any other aspects of the study. 
Patient advisers also include those listed as the Study 
Contributors.
study design and setting
This pilot study was an observational cohort biomarker 
study conducted in the Emergency Department and 
Emergency General Surgery Department at the Royal 
Infirmary of Edinburgh, National Health Service (NHS) 
Lothian, UK.
Inclusion and exclusion criteria
All adult patients referred to the on-call general surgeons 
with acute abdominal pain, irrespective of the charac-
teristics of the pain and with a differential diagnosis of 
gallstone disease on index presentation were eligible for 
inclusion. Patients must have had presented to hospital 
within 24 hours prior to recruitment. Patients who were 
unable to give informed consent, or who refused to 
participate in the study, or who were younger than 16 
years of age or transferred from a hospital outside the 
NHS regional trust (NHS Lothian) were excluded from 
the study.
study population, sample size and data collection
This proof-of-concept research study was designed to 
inform a power calculation for a multicentre qualification 
study, and therefore the sample size was pragmatic. This 
study had been approved to recruit a total of 300 patients 
over a period of 2 years.
Recruitment was for 52 weeks: 3 September 2014 to 2 
September 2015. Potential participants were identified 
at the on-call general surgery team’s daily handover. 
All patients recruited to the study had given informed 
consent. Clinical details, imaging reports, operation 
findings and pathology reports were obtained from 
handwritten and electronic medical notes. Each patient 
was then followed up through the electronic record 
for a minimum of 3 months. Whole blood was sampled 
within 24 hours of hospital presentation into Ethylenedi-
aminetetraacetic acid (EDTA) vacutainer tubes (S-Mon-
ovette, Sarstedt), centrifuged at 1000xg for 15 min at 4°C 
and the plasma layer retained. The supernatant was then 
separated into aliquots and stored at −80°C until analysis.
Variables and definitions
Clinical data included patient demographics, routine 
laboratory blood and microbiology results, imaging inves-
tigations, and/or information on surgical interventions 
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and pathology results. The final diagnoses of the patients 
were determined by histopathology results, operative 
findings, imaging investigations and/or discharge scripts, 
following that hierarchy. Patients with a diagnosis of 
non-specific abdominal pain (NSAP) had normal inves-
tigation results and a definitive cause of their abdominal 
pain was not found. All patients with NSAP had under-
went imaging with USS and/or magnetic resonance chol-
angiopancreatography (MRCP). Patients with gallstone 
diseases were grouped into ‘uncomplicated’ and ‘compli-
cated’ categories: patients with ‘uncomplicated’ disease 
had either biliary colic (cholelithiasis in gallbladder) or 
aseptic choledocholithiasis (choledocholithiasis without 
clinical, laboratory or microbiological evidence of sepsis); 
patients with ‘complicated’ gallstone disease were defined 
as patients with significant clinical, laboratory or patho-
logical inflammation or infection, which included those 
with cholangitis (septic choledocholithiasis), cholecystitis 
or gallstone pancreatitis. Patients with ‘other’ diseases 
included patients with any other non-gallstone-related 
disease that was diagnosed by a clinical (eg, urinalysis), 
imaging or invasive (eg, endoscopy) investigation. Each 
specific diagnosis is given in the flow chart (figure 1).
total rnA extraction, quantitative real-time PCr and eLIsA 
analysis
Laboratory analyses of all biomarkers were carried out 
blinded to participant clinical data. Analysis of miR-122 
was carried out in the Centre for Cardiovascular Sciences, 
University of Edinburgh); HMGB1, flk-18 and cck-18 
laboratory analyses were carried out at the MRC Centre 
for Drug Safety Science, University of Liverpool.
miR was extracted from plasma using the miRNeasy 
Serum/Plasma Kit (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s protocol.17 18 Synthetic 
miR-39 (at 1.6×108 copies/µL) was spiked in as an internal 
control. miRs were measured with Taqman-based quan-
titative PCR. Small RNA elutes were reverse transcribed 
using specific stem-loop reverse-transcription RT primers 
(Applied Biosystems, Foster City, California, USA) for each 
target miR species, following the manufacturer’s instruc-
tions. Specific stemloop rt primer targeting  UGG AGUG 
UGAC AAUG GUGUUUG and 5’  UCA CCGG GUGU 
AAAU CAGCUUG 3’ was used. No template controls were 
included to test for miR contamination. The expressions 
of miR-39 and miR-122 were analysed using the standard 
2-dct method19 normalised to the miR-39 spiked internal 
control.
Plasma HMGB1 and keratin-18 were determined by ELISA 
according to the manufacturer’s guidelines (Shino-Test/
IBL International20 21 for HMGB1; and PEVIVA22 for cck-18 
and flk-18) and our previously published protocols.5 23
statistical analysis
Continuous variables are presented as medians and IQR. 
Categorical variables are presented as frequencies. The 
Figure 1 Flow diagram for the main study. The number of patients who underwent cholecystectomy within each group is 
illustrated in brackets with an asterisk). #These  patients had gallstones as an incidental finding and strong evidence for other 
pathology to account for symptoms. CBD, common bile duct; CRP, C reactive protein; GB, gall bladder; GS, gallstones; HPB, 
hepatopancreaticobiliary; LFT, liver function test; LRTI, lower respiratory tract infection; MSK, musculoskeletal; NSAP, non-
specific abdominal pain; RCC, renal cell cancer; SMV, superior mesenteric vein; UGI, upper gastrointestinal; UTI, urinary tract 
infection; WCC, white cell count.
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Pearson’s χ2 test was used to examine the association 
between categorical variables. The Kolmogorov-Smirnov 
test was used to compare the distribution of non-para-
metric data against the normal distribution. The Krus-
kal-Wallis test was used to compare non-parametric 
variables followed by Dunn’s post hoc test for multiple 
comparisons. 95% CIs were calculated for all normally 
distributed continuous variables. Positive predictive 
value (PPV) and negative predictive value (NPV)  were 
used as the most relevant measures of clinical utility. 
Receiver operating characteristic (ROC) curve analyses 
were plotted for the different patient groups. Areas under 
the ROC curves were calculated with 95% CI. Sensitivity, 
PPV and NPV were obtained at 90% specificity. Spear-
man’s correlation was used to evaluate the correlation 
between age and gender in the cohort; linear regres-
sion was used to evaluate the effect of age (continuous 
variable) and gender (categorical variable) on biomark-
er-level expression (Stepping method criteria; Proba-
bility of F-entry 0.05; removal 0.10); backwards logistic 
Table 1 Demographics of the study cohort and routine blood test results
Overall NSAP* Uncomplicated† Complicated‡ Others P values
N (%) 289 (100) 47 (16.3) 64 (22.1) 115 (39.8) 63 (21.8)
Gender (n, (%))
  Male 88 (30.4) 3 (6.4) 9 (14.1) 53 (46.1) 23 (36.5) <0.001§ 
  Female 201 (69.6) 44 (93.6) 55 (85.9) 62 (53.9) 40 (63.5)
Age (years)
  Median 51.3 41.3 46.4 56.6 52.2 <0.001¶ 
  IQR 37.5–67.4 26.7–57.3 29.8–61.8 44.6–68.5 39.3–67.5
  95% CI 49.3 to 53.5 37.9 to 49.4 42.7 to 51.7 53.1 to 59.4 48.2 to 56.6
Underwent operation (n, (%))
  Yes 276 (44.6) 2 (4.3) 37 (57.8) 88 (76.5) 2 (3.2) <0.001§ 
  No 160 (55.4) 45 (95.7) 27 (42.2) 27 (23.5) 61 (96.8)
Duration from index presentation to operation (days)
  Median 3.0 1.5 4.0 3.0 24.0 0.067¶ 
  IQR 2.0–5.5 1.0 2.0–7.5 2.0–4.8 5.0
  95% CI 7.6 to 17.6 −4.9 to 7.9 4.1 to 25.2 5.8 to 17.6 −217.4 to 265.4
Total bilirubin (µmol/L)
  Median 14.0 11.0 22.5 17.0 11.0 <0.001¶ 
  IQR 8.0–31.5 7.0–15.0 10.3–46.8 9.0–35.0 7.0–33.0
  95% CI 24.3 to 32.7 10.2 to 14.2 25.9 to 44.1 23.3 to 35.6 19.8 to 44.6
Alanine aminotransferase, ALT (U/L)
  Median 36.0 23.0 135.0 38.0 41.0 <0.001¶ 
  IQR 19.0–169.5 14.0–29.0 23.5–359.0 20.0–178.0 18.0–100.0
  95% CI 119.2 to 174.1 20.9 to 32.2 175.7 to 336.5 106.6 to 185.2 71.4 to 181.5
Alkaline phosphatases, ALP (U/L)
  Median 96.0 76.0 139.5 94.0 94.0 <0.001¶ 
  IQR 71.0–172.5 60.0–103.0 86.0–264.0 70.0–158.0 74.0–238.0
  95% CI 137.9 to 172.0 75.2 to 101.3 153.1 to 223.0 121.7 to 170.5 135.8 to 238.7
Gamma-glutamyltranspeptidase, GGT (U/L)
  Median 87.0 25.0 238.0 114.5 74.0 <0.001¶ 
  IQR 30.0–389.5 14.0–54.0 55.0–457.5 39.3–392.5 30.0–497.8
  95% CI 211.4 to 312.7 24.9 to 54.5 236.5 to 422.1 178.9 to 358.3 187.4 to 437.3
*Non-specific abdominal pain.
†Biliary colic, aseptic choledocholithiasis.
‡Cholecystitis, cholangitis, gallstone pancreatitis.
§Pearson’s  χ2 test (for ‘gender’ and ‘underwent operation’).
¶Kruskal-Wallis test and Dunn’s multiple comparison test (for ‘age’, ‘duration from index presentation to operation’, ‘total bilirubin’, ‘ALT’, 
‘ALP’ and ‘GGT’).
NSAP, non-specific abdominal pain.
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regression (Probability for stepwise entry p=0.05 and 
removal from the model p=0.10, classification cut-off 
0.5, 20 iterations) was used to explore the confounding 
effect of age (as a continuous variable) and gender 
(as a categorical variable) on the association between 
biomarker levels (as continuous variables) and the pres-
ence of gallstones, or complicated gallstones (as sepa-
rate binary dependent variables). All statistical tests were 
based on a two-sided α-value of 0.05. Statistical analysis 
was performed using IBM SPSS Statistics V.19.0 (IBM) 
and G*Power V.3.1 (Universität Düsseldorf, Germany). 
Figures were designed, and correlation analyses were 
carried out using GraphPad Prism V.6.0 (GraphPad Soft-
ware, La Jolla, California, USA).
resuLts
study population
A total of 300 patients were screened for possible inclusion 
in the study. The study flow chart is presented in figure 1. 
Fifteen patients who had consented to participate in the 
study were excluded: two were transferred to a different 
hospital prior obtaining blood samples; one was under 16 
years old; five were admitted more than 24 hours prior to 
recruitment; two patients’ blood samples were collected 
in the wrong sample tube; one blood sample tube did 
not have the required volume for biomarker testing; four 
patients did not receive any imaging to determine a cause 
for their abdominal pain for reasons that we were unable to 
ascertain, but may have included premature self-discharge. 
Of the 285 patients included in the study, seven patients 
with an incidental finding of gallstones were excluded from 
data analysis as there was strong clinical and radiological 
evidence for a different pathology to account entirely for 
their symptoms. Forty-four (15.8%) patients had NSAP, 
64 patients (23.0%) had uncomplicated gallstone disease, 
121 patients (43.5%) had a complicated gallstone disease 
and 49 patients (17.7%) had other non-gallstone-related 
disease.
The demographics of the study subjects are illustrated 
in table 1. There were more females compared with males 
between the four patient groups (p<0.001). Patients with 
uncomplicated gallstone diseases (46.5 years (29.8–61.8)) 
were significantly younger than patients with complicated 
diseases (57.4 years (44.8–68.6); p<0.001). Serum alanine 
aminotransferase, alkaline phosphatase and gamma-glu-
tamyltranspeptidase activities were higher in patients with 
uncomplicated gallstone diseases compared with compli-
cated diseases.
Of the 278 patients included for data analysis, 129 
patients (46.4%) underwent a cholecystectomy. There 
was no difference in the time period from patient’s 
index hospital presentation to the day of operation 
between patient with (median: 3.0 days (2.0–5.0)) and 
without (median: 4.0 days (2.0–7.5)) complications 
of gallstones (p=0.137). Interestingly, there was no 
statistical difference between the two gallstone disease 
Table 2 Biomarker concentrations
Overall NSAP* Uncomplicated† Complicated‡ Others P values§
miR-122 (x104 copies/mL)
  Median 1.81 0.90 5.72 2.26 1.13 <0.001
  IQR 0.54–7.0 0.41–2.23 0.97–16.85 0.75–7.86 0.42–4.42
  95% CI 6.21 to 16.40 4.32 to 26.42 9.51 to 22.24 1.54 to 22.82 2.26 to 8.23
HMGB1 (ng/mL)
  Median 2.34 2.08 2.60 2.29 2.70 0.584
  IQR 1.34–3.55 1.26–3.50 1.30–4.67 1.44–3.37 1.18–4.16
  95% CI 2.13 to 2.60 1.50 to 2.59 2.05 to 3.01 2.02 to 2.56 1.90 to 3.10
cck-18 (U/L)
  Median 114.60 100.33 139.71 111.35 114.84 0.009
  IQR 87.40–171.53 75.05–135.40 98.15–228.71 87.17–171.83 87.12–181.26
  95% CI 105.02 to 123.67 87.23 to 112.47 121.82 to 168.56 100.31 to 134.24 95.27 to 125.78
flk-18 (U/L)
  Median 202.99 107.08 322.55 236.34 205.54 <0.001
  IQR 102.63–450.55 66.39–168.43 133.43–662.04 136.63–429.38 101.81–462.56
  95% CI 170.60 to 237.24 78.90 to 149.70 202.10 to 479.32 184.91 to 304.06 151.78 to 325.69
*Non-specific abdominal pain.
†Biliary colic, aseptic choledocholithiasis.
‡Cholecystitis, cholangitis, gallstone pancreatitis.
§Kruskal-Wallis test and Dunn’s multiple comparison test.
cck-18, caspase-cleaved keratin-18; flk-18, full-length keratin-18; HMGB1, high-mobility group box 1; miR-122, microRNA-122; NSAP, non-
specific abdominal pain. 
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subgroups (uncomplicated: n=11, 17.2% vs compli-
cated: n=24, 19.8%; p=0.664) with regard to CT and 
MRCP investigation (uncomplicated: n=34, 53.1% vs 
complicated: n=47, 38.8%; p=0.063) (online supple-
mentary table 1).
high-mobility group box 1
There was no significant difference in plasma HMGB1 
concentration between patients with and without gall-
stone disease (gallstone diseases: 2.41 ng/mL (1.40–
3.53); non-gallstones: 2.41 ng/mL (1.26–3.73); p=0.559) 
Table 3 Biomarker evaluation by receiver operator characteristics
ROC AUC (95% CI) Sensitivity (%) (95% CI) PPV (%) NPV (%) P values* 
miR-122
  Gallstone versus non-gallstone† 0.66 (0.59 to 0.72) 16 (10 to 25) 72.5 39.8 <0.001
  Uncomplicated‡ versus complicated§ 0.60 (0.51 to 0.69) 22 (15 to 30) 56.0 67.5 0.022
cck-18
  Gallstone versus non-gallstone† 0.57 (0.50 to 0.64) 6 (3 to 13) 50.0 7.1 0.041
  Uncomplicated‡ versus complicated§ 0.59 (0.50 to 0.68) 14 (8 to 22) 45.0 65.4 0.049
flk-18
  Gallstone versus non-gallstone† 0.63 (0.56 to 0.70) 20 (13 to 29) 76.6 40.9 <0.001
  Uncomplicated‡ versus complicated§ 0.56 (0.47 to 0.65) 12 (7 to 20) 42.1 65.0 0.160
*Kruskal-Wallis test and Dunn’s multiple comparison test.
†NSAP and other diseases.
‡Biliary colic, aseptic choledocholithiasis.
§Cholecystitis, cholangitis, gallstone pancreatitis.
AUC, area under the curve; cck-18, caspase-cleaved keratin-18; flk-18, full-length keratin-18; miR, microRNA-122; NPV, negative predictive 
value; NSAP, non-specific abdominal pain; PPV, positive predictive value; ROC, receiver operating characteristic.   
Figure 2 (A) Plasma microRNA-122 (miR-122) values in gallstone and non-gallstone diseases normalised to miR-39. Each data 
point represents an individual. The horizontal line in each patient group represents the median value. Statistical significances (p 
value) by Kruskal-Wallis test and Dunn’s multiple comparison test are shown in the figure for between-group comparison. (B) 
Receiver operating characteristic (ROC) curve of miR-122 for gallstone versus non-gallstone diseases. (C) miR-122 values for 
the four main patient groups. (D) ROC curve of miR-122 values for uncomplicated versus complicated gallstone diseases. AUC, 
area under the curve; NSAP, non-specific abdominal pain; SENS, sensitivity. 
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or between the four different study groups (p=0.964) 
(table 2 and online supplementary figure 1).
micrornA-122
miR-122 in gallstone diseases and non-gallstone diseases
Circulating miR-122 concentration was higher in patients 
with gallstone disease than in those without gallstones 
(2.89×104 copies/mL (0.89–9.91×104) vs 0.90×104 copies/
mL (0.36–2.73×104); p<0.001) (figure 2A). ROC curve 
analysis (figure 2B) of miR-122 for patients with and 
without gallstone disease produced an area under the 
curve (AUC) of 0.68. The calculated PPV and NPV at 90% 
specificity were 77.5% and 35.3%, respectively (table 3).
miR-122 in uncomplicated and complicated gallstone diseases
Patients with uncomplicated gallstone disease had a 
significantly higher miR-122 concentration than those 
with complicated gallstone disease (5.72×104 copies/mL 
(0.97–16.85×104) vs 2.26×104 copies/mL (0.78–7.88×104); 
p=0.023) (table 2 and figure 2C). ROC analysis (figure 2D) 
comparing uncomplicated and complicated gallstone 
diseases yielded an AUC of 0.60 (table 3) (online supple-
mentary figure 2 and supplementary tables 2 and 3 illus-
trate the gallstone disease subgroups).
Caspase-cleaved keratin-18
cck-18 in gallstone diseases and non-gallstone diseases
Plasma cck-18 concentration was significantly higher 
in patients with gallstone disease than those without 
(121.20 U/L (89.92–180.42) vs 103.46 U/L (83.90–
147.13); p=0.031) (figure 3A). A ROC curve analysis of 
cck-18 in patients with and without gallstones yielded an 
AUC of 0.58 (figure 3B), with a calculated PPV of 62.5% 
and NPV of 32.9% (table 3).
cck-18 in uncomplicated and complicated gallstone diseases
cck-18 concentration was higher in patients with uncom-
plicated (139.71 U/L (98.15–228.71)) gallstone diseases 
than those with complications (113.60 U/L (87.73–
171.57)), p=0.047) (table 2 and figure 3C). This trans-
lated to an AUC of 0.59 (figure 3D) with PPV of 40.0% 
and NPV of 66.1% at 90% specificity (table 3) (online 
supplementary figure 3 and supplementary tables 3 and 4 
illustrate gallstone disease subgroups).
Full-length keratin-18
flk-18 in gallstone diseases and non-gallstone diseases
Similarly, flk-18 concentration was significantly higher 
in patients with gallstone disease than those without 
(252.38 U/L (137.41–521.27) vs 145.06 U/L (75.97–
292.34); p<0.001) (figure 4A). A ROC curve analysis 
(figure 4B) of flk-18 in patients with and without gall-
stones yielded an AUC of 0.65 (table 3).
flk-18 in uncomplicated and complicated gallstone diseases
There was no significant difference in flk-18 concentration 
between the two subgroups of gallstone diseases (p=0.154) 
(table 2 and figure 4C,D) (online supplementary figure 4 
Figure 3 (A) Plasma concentrations of caspase-cleaved keratin-18 (cck-18) protein in gallstone and non-gallstone diseases. 
Each data point represents an individual. The horizontal line in each patient group represents the median value. Statistical 
significances (p value) by Kruskal-Wallis test and Dunn’s multiple comparison test are shown in the figure for between-group 
comparison. (B) Receiver operating characteristic (ROC) curve of cck-18 for gallstone versus non-gallstone diseases. (C) cck-
18 values for the four main patient groups. (D) ROC curve of cck-18 values for uncomplicated versus complicated gallstone 
diseases. AUC, area under the curve; NSAP, non-specific abdominal pain; SENS, sensitivity.
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and online supplementary tables 3 and 5 illustrate gall-
stone disease subgroups).
effect of age and gender on biomarkers
Because increasing age and being women exhibited a 
statistically significant correlation in the cohort (Spear-
man’s r=0.285, p<0.001), we checked whether there was 
an independent effect of age and gender on any of the 
biomarker levels by linear regression. Biomarker levels 
were not independently associated with age or gender 
(online supplementary table 6). Furthermore, when we 
examined potential confounding by age and gender on 
the utility of the biomarker values to detect gallstones 
by backwards logistic regression, none of age, gender 
or any biomarker was independently associated with the 
presence of gallstones (online supplementary table 7). 
For detecting complications of gallstones, using logistic 
regression, no biomarker was independently associ-
ated with the presence of complicated gallstones, but 
increasing age (OR 1.02; 95% CI 1.01 to 1.04; p=0.002) 
and female gender (OR 3.10; 95% CI 1.77 to 5.41; 
p<0.001) increased the likelihood of a positive diagnosis 
of complicated gallstones (online supplementary table 8). 
Using logistic regression individually for each biomarker 
did not alter the lack of independent association with the 
presence of complicated gallstones (online supplemen-
tary tables 9–12).
DIsCussIOn
Early identification of individuals with potentially serious 
complications of gallstones from the denominator pool 
of all persons presenting with biliary-type symptoms is 
of translational importance. In this study, we report that 
plasma miR-122, cck-18 and flk-18 concentrations were 
significantly higher in patients with gallstone diseases 
than in non-gallstone diseases. However, the degree of 
overlap between groups was high, thus detracting from 
the utility of this approach to accurately stratify on an 
individual patient basis.
The biomarkers measured in this paper have robust 
evidence supporting their utility in preclinical models 
and the clinical setting for the early, sensitive and 
Figure 4 (A) Plasma full-length keratin-18 (flk-18) protein concentrations in gallstone and non-gallstone diseases. Each data 
point represents an individual. The horizontal line in each patient group represents the median value. Statistical significances (p 
value) by Kruskal-Wallis test and Dunn’s multiple comparison test are shown in the figure for between-group comparison. (B) 
Receiver operating characteristic (ROC) curve of flk-18 for gallstone versus non-gallstone diseases. (C) flk-18 concentrations for 
the four main patient groups. (D) ROC curve of flk-18 values for uncomplicated versus complicated gallstone diseases. AUC,  
area under the curve; NSAP,  non-specific abdominal pain; SENS, sensitivity. 
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specific identification of hepatocellular injury following 
paracetamol overdose (an archetypal hepatocyte toxic 
agent) and also hypoxic hepatitis. Published papers have 
suggested this panel of biomarkers may also have utility 
with regard to acute cholestatic pathology induced by 
gallstones.4–6 9 10 15 16
Our finding that plasma miR-122 concentration was 
increased in patients with gallstones agrees with that of 
Shifeng et al,6 who compared their disease cohort with 
‘healthy’ control groups. However, their study yielded a 
much higher AUC on the ROC analysis, 0.93 with 77.4% 
sensitivity and 96.4%. The probable explanation for this is 
that our comparison group was patients admitted acutely 
under general surgery with a non-gallstone-related diag-
nosis, who therefore may have had deranged inflamma-
tory markers and/or LFTs due to another pathological 
process. This demonstrates the importance of clinically 
relevant control groups in biomarker discovery and vali-
dation studies.
In the present study, there was no significant difference 
in plasma HMGB1 concentration across all comparisons. 
This is consistent with a study by Shi et al9 which demon-
strated HMGB1 over expression in gallbladder cancers 
but not in benign GB tissues or cholelithiasis.
Plasma cck-18 and flk-18 were significantly higher in 
patients with gallstones, in agreement with studies by 
others16 24 who examined gallbladder tissue, bile and 
serum. In our study, patients with cholecystitis were 
not further subdivided into active/inactive and acute/
chronic subtypes due to sample sizing. Nevertheless, 
Simopoulos et al16 demonstrated no difference in total 
k-18 and cck-18 between active and inactive chronic 
cholecystitis.
We recognise some important limitations in this study. 
This was a pilot study to determine whether there is a 
signal of biomarker utility in this context of use to take 
forward into larger, multicentre studies. We believe that 
the results presented in this paper are clear in their failure 
to support utility with regard to patient stratification at 
hospital presentation. As demonstrated in our analysis, 
both age and gender are confounding factors in the 
association of biomarker concentrations with gallstone 
disease. Serial patient blood sampling for biomarker 
analyses may have also been useful to determine the 
true nature of biomarker concentration changes during 
the disease progress. However, should larger studies be 
able to show a much stronger association between these 
biomarkers and the complications of gallstones, these 
biomarkers could be used as diagnostic aids especially 
when combined with the current laboratory and imaging 
investigations available.
In conclusion, miR-122 and keratin-18 plasma concen-
trations are elevated in patients with gallstones. However, 
this result is confounded by the association between 
biomarker concentrations, age and gender. In this pilot 
study, miR-122 and keratin-18 were not sufficiently 
discriminatory to be progressed as clinically useful 
biomarkers in this context.
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